Miscellaneous Malignancies | Norton Healthcare

Indication: Miscellaneous Malignancies

A Phase 1 Study of ASP1948, Targeting an Immune Modulatory Receptor, in Subjects with Advanced Solid Tumors

Advanced Solid Tumors

Sub-indication: Subjects with SCCCHN, NSCLC, mCRPC, Ovarian, Pancreatic, Breast cancer

Line of Therapy: Subject needs to have failed all standard therapies

Drug Study

Principal Investigator: John Hamm, M.D.
Norton Cancer Institute

Sponsor: Astellas Pharma US, Inc

Learn more at ClinicalTrials.gov

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.